Investors reacted sharply on Thursday as Meta reported a dip into negative free cash flow, sending the company’s stock tumbling by approximately six percent. While the social media powerhouse saw a healthy twenty six percent jump in quarterly revenue to sixty four point six billion dollars, those gains were overshadowed by an aggressive increase in spending. The company has raised its projected annual capital expenditures to between one hundred thirty five billion and one hundred forty five billion dollars, signaling a massive financial commitment to its artificial intelligence ambitions.

This surge in spending sparked immediate anxiety regarding the firm’s creditworthiness, pushing five year credit default swaps to record highs. With free cash flow hitting negative two point twelve billion dollars for the quarter, some market participants are questioning whether the current pace of investment can be sustained without compromising stability. To help navigate these growth costs while preserving Mark Zuckerberg’s control over the organization, Meta announced the creation of a new class of nonvoting common stock designed to provide additional financing flexibility.

Beyond the balance sheet, corporate filings revealed personal tensions involving Zuckerberg and potential changes to California tax laws. According to documents submitted to the SEC, there were concerns that a proposed wealth tax in California could have prompted the CEO to relocate due to multi billion dollar liabilities tied to his holdings. However, the company indicated that the newly implemented stock plan served as a key incentive for him to remain in the state despite those fiscal pressures.

Moderna shares plummeted on Thursday following reports that confidential data regarding its highly anticipated cancer vaccine had been leaked by a third party. The sudden drop came just days before the company was scheduled to formally present its findings this coming Saturday at the European Society of Clinical Oncology Congress. Investors reacted swiftly to the unauthorized disclosure, sending the stock price sliding by twenty percent as uncertainty gripped the market over the actual results of the trial.

The experimental treatment, known as intismeran autogene, has been developed through a strategic partnership between Moderna and pharmaceutical giant Merck. While both companies have faced intense scrutiny and high expectations surrounding this specific project, neither organization provided an immediate response when contacted for comment regarding the leak or the validity of the disclosed information.

This volatility highlights the extreme sensitivity of biotech valuations to clinical data, where even a glimpse of preliminary numbers can trigger massive swings in investor confidence. With all eyes now turning toward the official presentation this weekend, shareholders are waiting to see if Merck and Moderna can stabilize the narrative or if the leaked data represents a fundamental setback for their oncology ambitions.

Investors reacted sharply on Thursday as Moderna shares plummeted up to 25 percent following an unauthorized leak of partial data regarding its highly anticipated cancer vaccine. The sudden selloff occurred even though the complete dataset, which was released shortly after the leak, actually outperformed many Wall Street expectations. Developed in partnership with Merck, the personalized treatment known as intismeran autogene aims to revolutionize how doctors approach melanoma.

The clinical findings revealed a significant leap in patient outcomes when the vaccine was paired with Merck’s immunotherapy drug, Keytruda. According to the data, the combination therapy reduced the risk of cancer recurrence or death by 42 percent compared to using Keytruda alone. Furthermore, there was a 38 percent reduction in the risk of cancer spreading to distant organs or resulting in death, marking what many experts consider a major step forward in oncology.

This volatility comes at a time when anticipation for Moderna’s pipeline has reached a fever pitch. The company’s stock had surged over 530 percent so far this year as investors bet on the firm diversifying beyond its famous Covid-19 shots into flu and RSV treatments. While Merck saw a minor dip of about 1 percent during Thursday’s trading session, both companies view this targeted vaccine as a potential blueprint for treating various other types of cancer in the future.

Despite the medical success, some logistical hurdles remain due to the bespoke nature of each dose. Currently, the complex manufacturing process takes roughly six weeks per patient. However, Merck CEO Robert Davis recently indicated that his team is working to streamline production timelines to ensure these life saving therapies can reach patients faster once they hit the market. Full details from the phase three trials are expected to be formally presented at the European Society for Medical Oncology conference this weekend.

Investors sent Spotify shares climbing ten percent on Thursday, pushing the stock to a ten month high after the company reported a stronger than expected surge in its subscriber base. The streaming leader reached 306 million premium subscribers during the September quarter, beating analyst predictions by one million and showing consistent growth across every region it operates in. This momentum is paired with a broader user base of 788 million monthly active users and revenue that climbed sixteen percent to five billion euros, signaling that the platform’s scale continues to accelerate despite a challenging economic climate.

Beyond the raw numbers, leadership highlighted a strategic pivot toward diversified audio content and cutting edge technology. Co CEOs Gustav Soderstrom and Alex Norstrom pointed to the massive success of video podcasts, which have seen consumption jump over 140 percent since launch. The company is also making an aggressive push into audiobooks, noting that these titles are nearly as popular as music in some markets like Sweden. With plans to expand audiobook access to 180 markets by the end of the year and a renewed deal with Joe Rogan, Spotify is positioning itself as a comprehensive audio hub rather than just a music app.

The company is leaning heavily into artificial intelligence to keep users engaged, introducing personalized taste profiles and a new integration with Metas Muse. These tools allow listeners to interact with an AI agent to curate deep dive playlists based on years of listening history or discover credits for specific performers. While embracing innovation, Spotify remains vigilant about quality control; executives revealed they have scrubbed millions of AI generated spam tracks from their recommendations over the last year to maintain the integrity of their discovery algorithms.

Financially, Spotify appears well positioned for long term stability thanks to low debt levels and a significant cash reserve, providing a safety net against volatile interest rates. Management expressed confidence in their ability to balance investment with cost moderation, guiding for another ten million net adds in the final quarter of the year. By diversifying into creators memberships and expanded partner programs across dozens of new markets, the firm believes it is building a compounding business model capable of thriving in what they call the agentic age of technology.

In a striking display of market divergence, shares of Nasdaq Inc. surged to an all time high on Thursday, proving that the house always wins even when the guests are losing. The exchange operator climbed into the prestigious Big Cap 20 list just as the very index it manages suffered a bruising decline. It is a rare moment where the platform providing the infrastructure for trading outperformed the collective value of the tech heavyweights it hosts.

The broader Nasdaq composite plummeted by 2.6 percent during the session, marking its steepest drop since early June. This sharp downturn was largely fueled by growing investor anxiety regarding corporate spending habits. Wall Street is increasingly worried that companies are burning through cash too quickly in a desperate race to dominate emerging technologies, leading to a wave of selling across several key sectors.

Despite this turmoil among its constituents, Nasdaq’s own stock remained resilient and bullish. By hitting a record peak while its index crashed, the company highlighted a fundamental disconnect between current valuations of individual tech firms and the enduring value of the financial exchanges they trade upon. For now, investors seem more confident in the toll booth than in those passing through it.